Regarding Hb response, our network meta-analysis included 20 RCTs involving the administration of 6 HIF-PHIs, rhEPO, DPO and MPG-EPO in 12,861 DD-CKD patients with anemia. This evidence concerns the gene GSTM1 and chronic kidney disease.